Opium (Opioid) Addiction - Pipeline Review, H2 2020

September 2020 | 193 pages | ID: O44D6D3C48BEN
Global Markets Direct

Abstracts

Opium (Opioid) Addiction - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2020, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.
Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 7, 13, 1, 29, 8 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 6 molecules, respectively.
Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Opium Addiction - Overview
Opium Addiction - Therapeutics Development
Opium Addiction - Therapeutics Assessment
Opium Addiction - Companies Involved in Therapeutics Development
Opium Addiction - Drug Profiles
Opium Addiction - Dormant Projects
Opium Addiction - Discontinued Products
Opium Addiction - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Opium (Opioid) Addiction, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Opium (Opioid) Addiction - Pipeline by Adial Pharmaceuticals Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Alar Pharmaceuticals Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Amygdala Neurosciences Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Antheia Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Aphios Corp, H2 2020
Opium (Opioid) Addiction - Pipeline by Aquilus Pharmaceuticals Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Benuvia Therapeutics Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by BioXcel Therapeutics Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Bridge Therapeutics Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2020
Opium (Opioid) Addiction - Pipeline by Cessation Therapeutics LLC, H2 2020
Opium (Opioid) Addiction - Pipeline by Closed Loop Medicine Ltd, H2 2020
Opium (Opioid) Addiction - Pipeline by Delpor Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by DemeRx Inc, H2 2020
Opium (Opioid) Addiction - Pipeline by Elysium Therapeutics Inc, H2 2020
Opium (Opioid) Addiction - Dormant Projects, H2 2020
Opium (Opioid) Addiction - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Opium (Opioid) Addiction, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Adial Pharmaceuticals Inc
Alar Pharmaceuticals Inc
Amygdala Neurosciences Inc
Antheia Inc
Aoxing Pharmaceutical Company Inc
Aphios Corp
Aquilus Pharmaceuticals Inc
Benuvia Therapeutics Inc
BioCorRx Inc
BioXcel Therapeutics Inc
Bridge Therapeutics Inc
Camurus AB
Cessation Therapeutics LLC
Closed Loop Medicine Ltd
Delpor Inc
DemeRx Inc
Elysium Therapeutics Inc
Emergent BioSolutions Inc
Ensysce Biosciences Inc
Eolas Therapeutics Inc
Epiodyne Inc
Ethismos Research Inc
Exxel Pharma Inc
Fab’entech SA
Gilgamesh Pharmaceuticals Inc
Indivior Plc
Inimmune Corp
Lyndra Therapeutics Inc.
Mayne Pharma Group Ltd
Mind Medicine Inc
Nirsum Laboratories Inc
Omeros Corp
Opiant Pharmaceuticals Inc
Orexigen Therapeutics Inc
Orexo AB
Orphomed Inc
Osmotica Pharmaceutical Corp
Palisades Therapeutics
Pharmazz Inc
Phoenix PharmaLabs Inc
Plumb Pharmaceuticals LLC
Proniras Corp
Sen-Jam Pharmaceutical LLC
Senzer Ltd
Serina Therapeutics Inc
Syntropharma Ltd
Titan Pharmaceuticals Inc
VDM Biochemicals Inc
Vivera Pharmaceuticals Inc
Yichang Humanwell Pharmaceutical Co Ltd
Zynerba Pharmaceuticals Inc